| Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease AJ Yarur, V Kanagala, DJ Stein, F Czul, MA Quintero, D Agrawal, A Patel, ... Alimentary pharmacology & therapeutics 45 (7), 933-940, 2017 | 299 | 2017 |
| Inflammatory bowel disease is associated with an increased incidence of cardiovascular events AJ Yarur, AR Deshpande, DM Pechman, L Tamariz, MT Abreu, ... Official journal of the American College of Gastroenterology| ACG 106 (4 …, 2011 | 282 | 2011 |
| The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study AJ Yarur, A Jain, DA Sussman, JS Barkin, MA Quintero, F Princen, ... Gut 65 (2), 249-255, 2016 | 260 | 2016 |
| Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis JP Brito, AJ Yarur, LJ Prokop, B McIver, MH Murad, VM Montori Thyroid 23 (4), 449-455, 2013 | 194 | 2013 |
| Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy AJ Yarur, MJ Kubiliun, F Czul, DA Sussman, MA Quintero, A Jain, ... Clinical Gastroenterology and Hepatology 13 (6), 1118-1124. e3, 2015 | 181 | 2015 |
| The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study AJ Panara, AJ Yarur, B Rieders, S Proksell, AR Deshpande, MT Abreu, ... Alimentary pharmacology & therapeutics 39 (8), 802-810, 2014 | 179 | 2014 |
| A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease AS Cheifetz, MT Abreu, W Afif, RK Cross, MC Dubinsky, EV Loftus Jr, ... Official journal of the American College of Gastroenterology| ACG 116 (10 …, 2021 | 135 | 2021 |
| Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists T Pérez-Jeldres, CJ Tyler, JD Boyer, T Karuppuchamy, A Yarur, DA Giles, ... Frontiers in pharmacology 10, 212, 2019 | 125 | 2019 |
| Predictors of aggressive inflammatory bowel disease AJ Yarur, SG Strobel, AR Deshpande, MT Abreu Gastroenterology & hepatology 7 (10), 652, 2011 | 120 | 2011 |
| Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn's disease and ulcerative colitis AJ Yarur, A Jain, SI Hauenstein, MA Quintero, JS Barkin, AR Deshpande, ... Inflammatory bowel diseases 22 (2), 409-415, 2016 | 117 | 2016 |
| Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies WJ Sandborn, S Vermeire, L Peyrin-Biroulet, MC Dubinsky, J Panes, ... The Lancet 401 (10383), 1159-1171, 2023 | 113 | 2023 |
| Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naïve inflammatory bowel disease patients: results from the EVOLVE study B Bressler, A Yarur, MS Silverberg, M Bassel, E Bellaguarda, C Fourment, ... Journal of Crohn's and Colitis 15 (10), 1694-1706, 2021 | 101 | 2021 |
| Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation FH Calmet, AJ Yarur, G Pukazhendhi, J Ahmad, KR Bhamidimarri Annals of gastroenterology: quarterly publication of the Hellenic Society of …, 2015 | 98 | 2015 |
| Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease B Christensen, PR Gibson, D Micic, RJ Colman, SR Goeppinger, ... Clinical Gastroenterology and Hepatology 17 (3), 486-493, 2019 | 95 | 2019 |
| Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the … B Christensen, D Micic, PR Gibson, A Yarur, E Bellaguarda, P Corsello, ... Alimentary pharmacology & therapeutics 47 (6), 753-762, 2018 | 84 | 2018 |
| Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis P Deepak, QA Alayo, A Khatiwada, B Lin, M Fenster, C Dimopoulos, ... Clinical Gastroenterology and Hepatology 19 (8), 1592-1601. e3, 2021 | 82 | 2021 |
| Development and validation of a test to monitor endoscopic activity in patients with Crohn’s disease based on serum levels of proteins G D’Haens, O Kelly, R Battat, MS Silverberg, D Laharie, E Louis, ... Gastroenterology 158 (3), 515-526. e10, 2020 | 81 | 2020 |
| Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives K Papamichael, W Afif, D Drobne, MC Dubinsky, M Ferrante, PM Irving, ... The lancet Gastroenterology & hepatology 7 (2), 171-185, 2022 | 80 | 2022 |
| Therapeutic drug monitoring in patients with inflammatory bowel disease AJ Yarur, MT Abreu, AR Deshpande, DH Kerman, DA Sussman World journal of gastroenterology: WJG 20 (13), 3475, 2014 | 74 | 2014 |
| Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases AJ Yarur, DT Rubin Inflammatory bowel diseases 21 (7), 1709-1718, 2015 | 70 | 2015 |
